EMA/145471/2022 Corr[1]

European Medicines Agency decision

P/0101/2022

of 17 March 2022

on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (Edurant), (EMEA-000317-PIP01-08-M13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

[1] 16 March 2023

European Medicines Agency decision

P/0101/2022

of 17 March 2022

on the acceptance of a modification of an agreed paediatric investigation plan for rilpivirine (hydrochloride) (Edurant), (EMEA-000317-PIP01-08-M13) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[2],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[3],

Having regard to the European Medicines Agency's decision P/144/2009 issued on 17 July 2009, the decision P/43/2010 issued on 31 March 2010, the decision P/242/2011 issued on 30 September 2011, the decision P/0030/2012 issued on 2 February 2012, the decision P/0192/2013 issued on 15 August 2013, the decision P/0323/2013 issued on 19 December 2013, the decision P/0194/2014 issued on 8 August 2014, the decision P/0344/2014 issued on 22 December 2014, the decision P/0012/2016 issued on 29 January 2016, the decision P/0206/2016 issued on 12 August 2016, the decision P/0322/2018 issued on 12 September 2018, the decision P/0205/2019 issued on 12 June 2019 and the decision P/0291/2020 issued on 12 August 2020,

Having regard to the application submitted by Janssen-Cilag International NV on 19 November 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 February 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[2] OJ L 378, 27.12.2006, p.1, as amended.
[3] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for rilpivirine (hydrochloride) (Edurant), film-coated tablet, age-appropriate solid oral formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Janssen-Cilag International NV, Turnhoutseweg 30, 2340 – Beerse, Belgium.

EMA/PDCO/709207/2021
Amsterdam, 25 February 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000317-PIP01-08-M13

Scope of the application

Active substance(s):

Rilpivirine (hydrochloride)

Invented name:

Edurant

Condition(s):

Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate solid oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Janssen-Cilag International NV

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International NV submitted to the European Medicines Agency on 19 November 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European

Medicines Agency's decision P/144/2009 issued on 17 July 2009, the decision P/43/2010 issued on 31 March 2010, the decision P/242/2011 issued on 30 September 2011, the decision P/0030/2012 issued on 2 February 2012, the decision P/0192/2013 issued on 15 August 2013, the decision P/0323/2013 issued on 19 December 2013, the decision P/0194/2014 issued on 8 August 2014, the decision P/0344/2014 issued on 22 December 2014, the decision P/0012/2016 issued on 29 January 2016, the decision P/0206/2016 issued on 12 August 2016, the decision P/0322/2018 issued on 12 September 2018, the decision P/0205/2019 issued on 12 June 2019 and the decision P/0291/2020 issued on 12 August 2020.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 4 January 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of human immunodeficiency virus (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- film-coated tablet, age-appropriate solid oral formulation, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition

Treatment of human immunodeficiency virus (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Rilpivirine is indicated in combination with other antiretroviral (ARV) medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in ARV-naïve paediatric patients from 2 to less than 18 years with a baseline viral load below 100,000 HIV-1 RNA copies / ml.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate solid oral formulation

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of age-appropriate formulation for oral use
Non-clinical studies	Not applicable
Clinical studies	**Study 2** Open-label, randomised, crossover trial to compare the oral bioavailability of the age appropriate oral paediatric formulation of rilpivirine hydrochloride relative to that of the 25 mg tablet and to assess the food effect. (TMC278IFD1008)

	Study 3 Open-label, non-comparative trial to evaluate pharmacokinetics, safety, tolerability and antiviral activity of rilpivirine (as hydrochloride) in HIV-1 infected treatment-naïve adolescents from 12 years to less than 18 years of age. (TMC278-TiDP38-C213 – Cohort 1) **Study 4** Open-label, non-comparative trial to evaluate pharmacokinetics, safety, tolerability and antiviral activity of rilpivirine (as hydrochloride) in HIV-1 infected treatment-naïve children from 6 years to less than 12 years of age. (TMC278-TiDP38-C213 – Cohort 2) ***Study 5*** *deleted in procedure EMEA-000317-PIP01-08-M11.* **Study 6** *(added in procedure EMEA-000317-PIP01-08-M11)* Open-label, non-comparative trial to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of switching to rilpivirine (in combination with other antiretrovirals) in HIV-1-infected children from 2 years to less than 12 years of age who are virologically suppressed. (TMC278HTX2002)
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Human Immunodeficiency Virus (HIV-1) infection

Authorised indication(s):

- EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 12 years of age and older with a viral load ≤ 100,000 HIV-1 RNA copies/ml.

  Genotypic resistance testing should guide the use of EDURANT (see sections 4.4 and 5.1).

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use